Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...
Viking Therapeutics Inc (NASDAQ:VKTX) announced that new clinical data from the company’s VK2735 obesity program were ...
The Motley Fool on MSN1d
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green FlagThe company's latest presentation supports the idea that its lead program will make billions.
Shares of Viking Therapeutics, Inc. (VKTX) were gaining around 17 percent in the pre-market activity on the Nasdaq after the company ...
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased ...
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics (VKTX – Research ...
Despite reduction in VK2735 exposure, significant reductions in body weight were observed, with subjects reporting mean body weight change of -4.0% from baseline at Day 28 (p0.0001). Weight loss ...
Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback